| Coulson, J.M., Adams, A., Gray, L.A. and Evans, A. 2022. COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy. Journal of Infection 85 (4) , pp. 436-480. 10.1016/j.jinf.2022.06.011 |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (7MB) | Preview |
License URL: http://creativecommons.org/licenses/by-nc-nd/4.0/
License Start date: 6 September 2023
Official URL: https://doi.org/10.1016/j.jinf.2022.06.011
Abstract
The efficacy of nirmatrelvir/ritonavir, an orally active chymotrypsin-like cysteine protease inhibitor in combination with a CYP3A4 inhibitor, in reducing hospitalisation or death from COVID-19 infection has been demonstrated in a high-risk adult population.1 Treatment within five days of COVID-19 symptoms was associated with a progressive reduction in viral load compared to the placebo arm; the duration of COVID-symptoms and changes in symptom severity were not reported.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine |
| Additional Information: | License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc-nd/4.0/, Start Date: 2023-09-06 |
| Publisher: | British Infection Association |
| ISSN: | 0163-4453 |
| Date of First Compliant Deposit: | 21 October 2022 |
| Date of Acceptance: | 13 June 2022 |
| Last Modified: | 06 Sep 2023 14:44 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/152439 |
Citation Data
Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric